It was a pleasure to speak with Prof. Eamonn Quigley (Houston Methodist Hospital, Houston, TX, USA) about the phase 2 study of the single-strain live biotherapeutic, Blautia hydrogentrophica (Blautix), currently under investigation in irritable bowel syndrome (IBS).
His abstract entitled ‘A Phase 2 Study of Live Biotherapeutic Blautix in Irritable Bowel Syndrome (IBS) Patients with subtypes IBS-C and IBS-D’ (Sa607) was presented at DDW, 21-23 May 2021.
Questions
- What are the limitations of current treatments for IBS? (0:28)
- What is Blautix and what is the rationale for its use in the treatment of adults with IBS-C and IBS-D? (01:29)
- Could you tell us a little about the aims and design of the Phase II study you presented? (2:37)
- What are the efficacy and safety findings by region and what was the reason for the differences? (03:46)
Disclosures: Prof Eamonn Quigley has received research support, and acted as a consultant to 4D Pharma.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of DDW 2021 (Virtual).
